Chapter 5 — How Toxins Cause Heart Failure
The Only Cause of Disease: Healing by Reversing Pathology — Thomas E. Levy, MD, JD
Part 1 of 7; physical source pages 143–148.
Book introduction and complete contents · Previous section · Next section · Next part
Editorial notice — separate from the source: This is a faithful reproduction of the author’s published source, not an I-OM clinical guideline or endorsement of every claim. It is educational material, not individualized medical advice. The source’s original disclaimers and copyright notices are retained. Safety note: Do not use this reproduction as instructions for self-treatment. Hydrogen peroxide mist can irritate the respiratory tract; higher exposures can cause serious lung injury. See CDC/ATSDR safety guidance.
Source page 143
Open original page 143 — full-size image
Chapter 5 A man dies when he refuses to take a stand for that which is true. Martin Luther King, Jr.
How Toxins Cause Heart Failure
General Heart Assessment Cardiomyopathy, which simply means heart muscle disease, can occur as a primary affliction of the heart muscle, as a secondary condition negatively impacting heart function, or as a combination of both. 1-3 Heart failure is a clinical diagnosis that describes the severity of limitations in cardiac output, or the amount of blood the heart is capable of pumping. For the practicing clinician, the most critical considerations in approaching the cardiomyopathy patient with clinical heart failure are: ✓ Is the heart muscle itself diseased? ✓ Is the heart muscle normal, but being forced into failure by non-cardiac factors? ✓ Is the clinical presentation a combination of both these conditions? ✓ Is the treatment protocol aimed only at relieving symptoms or also at resolving the underlying pathology resulting in clinical heart failure? 143
Source page 144
Open original page 144 — full-size image
144 THE ONLY CAUSE OF DISEASE
Because cardiomyopathy presenting in clinical heart failure is a condition often involving multiple factors, there is no single treatment protocol that can be considered optimal. Furthermore, heart failure rarely occurs in isolation without other diseases and co-morbid conditions being present and contributing to its symptoms as well. 4-5 However, all presentations of heart failure share features that must be addressed, regardless of whatever other treatments are being administered. The enormous public health impact of heart failure cannot be overstated. In Germany, for example, heart failure is the most common primary inpatient diagnosis. 6
Heart Failure Pathophysiology When the function of the heart is impaired sufficiently to decrease the amount of blood that should be pumped with every heartbeat (cardiac output), a clinical picture of heart failure will eventually emerge. As the body can clinically compensate reason- ably well for early heart failure, it is only when the decreased function is severe enough and chronic enough that heart failure symptoms become clear-cut. Because of this, even seemingly mild heart failure symptoms should be taken very seriously, with a complete diagnosis (especially in the ongoing pandemic setting), and the application of scientifically based treatments to support and improve heart function. Common symptoms of heart failure include the following, due basically to the abnormal accumulation of fluid in the lungs and the rest of the body from inadequate heart pumping ability: 7-8 ✓ Shortness of breath at rest or too quickly with exertion ✓ Shortness of breath when lying flat ✓ Waking up suddenly short of breath ✓ Fatigue
Source page 145
Open original page 145 — full-size image
How Introduction Toxins Cause Heart Failure 145
✓ Swelling in feet, ankles, and eventually legs and/or abdomen ✓ Accelerated heart rate, palpitations ✓ Heart muscle cells do not just fail and “wear out” for no reason. When oxidative stress increases within heart cells (myocytes), inflammation, by definition, also exists there. Additionally, part of the increased oxidative stress is attributed to a decrease in ATP (adenosine triphosphate) production in the mitochondria of heart cells. As ATP is the primary energy-providing molecule in the body, heart cells with compromised ATP production experience increased oxidative stress, resulting in a clinical picture of inflammation, or myocarditis. When the factors increasing oxidative stress are intense and acute in onset, rapid heart enlargement with poor heart contraction (congestive cardiomyopathy) will result. However, when the factors increasing oxidative stress are less intense and more chronic, the heart will generally first “adapt” by increasing the heart wall thick- ness without enlargement of the left ventricular dimensions (hyper- trophic cardiomyopathy). A clinical picture of heart failure will still be present and continue to evolve as the heart wall thickens, making the left ventricle stiffer and less compliant. This results in the heart chamber not filling up as readily (diastolic heart failure, or heart failure with preserved ejection fraction) 9-10 Effectively, this form of cardiomyopathy consumes more ATP trying to fill the heart than it does to pump and empty it. 11 With this resistance to heart chamber filling, the amount of blood pumped with each heartbeat eventually decreases, and the blood supply coming into that chamber “backs up,” resulting in the heart failure symptoms noted above. To be discussed below, toxins cause both forms of cardiomyopathy. Left untreated, the terminal stages of hypertrophic cardiomyopathy evolve into a congestive cardiomyopathy, with substantial enlargement of the
Source page 146
Open original page 146 — full-size image
146 THE ONLY CAUSE OF DISEASE
left ventricle and very poor contractility. This will result even when the heart was not enlarged or poorly contracting at the onset of the myocardial inflammation. The initial clinical presentation of heart failure is roughly split equally between hypertrophic and congestive cardiomyopathy. 12 Loss of functioning heart muscle is commonly considered to be the cause of congestive cardiomyopathy most of the time. This is undoubtedly a major reason for heart failure when multiple heart attacks with death of heart muscle and fibrotic scarring are present in place ...toxins cause of contracting heart muscle. However, both forms of heart biopsies in consecutive patients with advanced coronary artery block- cardiomyopathy. ages and clinical heart failure indi- Left untreated, the cated otherwise. The microscopic terminal stages evaluation of these biopsies indi- of hypertrophic cated that myocarditis (heart muscle cardiomyopathy inflammation) was the underlying evolve into cause, and heart function in some of these patients improved dramatically a congestive with anti-inflammatory measures. In cardiomyopathy, the absence of active ischemia or old with substantial heart attacks with extensive loss of enlargement of heart tissue, it is erroneous to consider the left ventricle ischemia as a primary cause of conges- and very poor tive heart failure, except to the degree that it increases oxidative stress in the contractility. remaining heart muscle. The crucial takeaway point is that myocarditis is not necessarily an obvious diagnosis. There must be a lower threshold for taking heart tissue biopsies, as missing the diagnosis of a treatable condition greatly increases morbidity and mortality for many patients. 13
Source page 147
Open original page 147 — full-size image
How Introduction Toxins Cause Heart Failure 147
Toxins and the Heart While toxin accumulation in the heart muscle can be the singular cause of advanced heart failure, it will much more often be one of several factors contributing to decreased heart contrac- tility and function. Also, the chronicity of heart failure, regardless of cause, will play a significant role in determining its reversibility, as more inflamed heart cells will eventually die. As cells die, the loss of function is more permanent and not just related to how well chronically inflamed cells can subsequently recover. Such inflamma- tion is consistently seen on the microscopic study of heart biopsies in toxin- and infection-related cardiomyopathy. 14-15 Various toxins, including many heavy metals, have been either linked to heart failure or clearly shown to be the direct cause. Heavy metals significantly increase oxidative stress and promote disease wherever they accumu- late. 16-21 Furthermore, one or more of these heavy metals are nearly always present in high concentrations in the poorly contracting heart muscle. A partial list of such agents includes the following: ✓ Lead ✓ Copper ✓ Iron ✓ Mercury ✓ Aluminum ✓ Cobalt/Chromium ✓ Cadmium ✓ Gold/Silver ✓ Chemotherapy ✓ COVID Spike protein
Lead: In a 3-year-old girl with chronic lead poisoning, acute heart failure developed that was clinically reversed after four days of
Source page 148
Open original page 148 — full-size image
148 THE ONLY CAUSE OF DISEASE
calcium EDTA chelation therapy. 22 Children who died from heart failure secondary to acute lead poisoning were documented to have the microscopic findings of myocarditis. 23 Lead has been shown in other studies to target the heart and the vascular system. 24-27 Animal studies have also shown that enough lead exposure will reliably cause myocarditis and vascular damage, as is seen in humans. These studies demonstrate that lead exposure can promote atherosclerosis and high blood pressure as well. 28-30
Copper: A transition metal necessary for normal cell function but easily pushed to excess and toxic levels in the body, copper is another culprit toxin commonly involved in cardiomyopathy patients. 31 Excess copper appears to be espe- cially toxic to the heart, as the infusion of copper into the coronary circu- ...a clear diagnosis lation of rats results in impaired of copper excess heart function in only minutes. 32 does not need to Hypertrophic cardiomyopathy has been strongly linked to the excess be made before copper levels seen in Wilson’s disease. treating patients Trientine, a selective copper chelator, presumptively as has been shown to improve cardiac having too much function in patients with hypertrophic cardiomyopathy. 33 copper in their In a randomized, placebo-con- heart, especially when trolled trial of diabetic patients with heart wall thickening left ventricular thickening (which can is present in a lead to hypertrophic cardiomyop- diabetic patient. athy), copper chelation significantly decreased heart wall thickening. This study did not even screen for elevated copper levels. 34-35 Furthermore, trientine chelation in diabetic rats with advanced left ventricular failure over an eight-week period demonstrated significantly improved heart function. 36 Another
Book introduction and complete contents · Previous section · Next section · Next part